RADNOR, Pa., Aug. 31, 2011 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening acute cardiovascular disorders and infectious diseases, has appointed Daniel M. Jorgensen as Senior Vice President, Clinical Development and Chief Medical Officer. In this role, Dr. Jorgensen will be responsible for implementing PolyMedix’s global clinical strategy.
